Halozyme Therapeutics, Inc. (HALO)

69.29 +2.65 (+3.98%) USD  |  NASDAQ  |  Apr 17, 16:00
69.44 +0.15 (+0.22%) Pre-Market: 08:30
More

Halozyme Therapeutics SG&A Expense (Quarterly) : 77.03M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Johnson & Johnson 0.00
Eli Lilly & Co. 3.132B
Vertex Pharmaceuticals, Inc. 487.00M
Baxter International, Inc. 761.00M
Glaukos Corp. 94.70M